Merck & Co. Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-10-16
Other years: 2026 vs 2025
⚠ AI Risk Brief Interpretation layer — deterministic data below

Merck significantly elevated AI and China exposure risks while reinforcing operational complexity across manufacturing, regulatory, and geopolitical dimensions.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

2
New Risks
0
Removed
11
Modified
20
Unchanged
🟢 New in Current Filing Disclosure change10/10

The Company is increasing its use of artificial intelligence (AI) systems to automate processes, analyze data, and support decision-making which poses inherent risks.

🟢 New in Current Filing The Company’s business in China has grown in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. In 2024, the Company experienced lower sales of Gardasil/Gardasil 9 in China and expects that sales of Gardasil/Gardasil 9 in China will decline significantly in 2025. 🔒
🟡 Modified The Company is increasingly dependent on sophisticated software applications and computing infrastructure, including the use of cloud-based applications and environments. The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations. 🔒
🟡 Modified The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition. 🔒

And 9 more changes in the full comparison.

12 changes in this historical filing

The complete historical comparison (2025 vs 2024) is available on the Pro plan.

Get Pro access Already a Pro subscriber? View full diff →